载有多柔比星的药物洗脱微球化疗栓塞术治疗胆管癌

Chemoembolization with Drug-eluting Microspheres Loaded with Doxorubicin for the Treatment of Cholangiocarcinoma.

作者信息

Aliberti Camillo, Carandina Riccardo, Sarti Donatella, Pizzirani Enrico, Ramondo Gaetano, Mulazzani Luca, Mattioli Gian Maria, Fiorentini Giammaria

机构信息

Oncology Radiodiagnostics, Oncology Institute of Veneto, Institute for the Research and Treatment of Cancer (IRCC), Padua, Italy.

Oncology Unit, Agency Reunited Hospital of North Marche, Pesaro, Italy.

出版信息

Anticancer Res. 2017 Apr;37(4):1859-1863. doi: 10.21873/anticanres.11522.

DOI:10.21873/anticanres.11522

PMID:28373452

Abstract

AIM

To report clinical outcomes of transarterial chemoembolization (TACE) using drug-eluting beads (DEBs) loaded with doxorubicin for the treatment of unresectable intrahepatic cholangiocarcinoma (CCA).

PATIENTS AND METHODS

We treated 127 patients with doxorubicin via TACE. Inclusion criteria were: diagnosis of unresectable CCA; indication for TACE, performance status (PS) 0-2, >3 months of life expectancy, >18 years old, written consent. TACE was performed using DEBs for 109 (86%) patients and polythylene glycol drug-elutable microspheres (PEG) loaded with doxorubicin for 18 (14%) patients.

RESULTS

Tumor response of the whole sample of 127 patients was partial response (PR) in 19 (15%) patients, stable disease (SD) in 101 (80%) and progressive disease (PD) in seven (5%) 3 months after therapy, with no complete responses. There were differences between type of embolics: PR was 7% and 77%, SD was 88% and 8%, and PD was 5% and 15%, and the disease control rate was 95% and 85% in the DEB and PEG groups, respectively. Most frequent side-effects were: abdominal pain, fever, nausea, and transaminase rise.

CONCLUSION

TACE was effective and safe for CCA treatment, with a high disease control rate. The best response of PEG-TACE was PR, whereas it was SD for DEB-TACE.

摘要

目的

报告使用载有阿霉素的药物洗脱微球（DEB）经动脉化疗栓塞术（TACE）治疗不可切除性肝内胆管癌（CCA）的临床结果。

患者与方法

我们通过TACE治疗了127例阿霉素患者。纳入标准为：诊断为不可切除性CCA；TACE适应症，体能状态（PS）0 - 2，预期寿命>3个月，年龄>18岁，书面同意。109例（86%）患者使用DEB进行TACE，18例（14%）患者使用载有阿霉素的聚乙二醇可洗脱微球（PEG）进行TACE。

结果

127例患者的整个样本在治疗3个月后的肿瘤反应为部分缓解（PR）19例（15%），疾病稳定（SD）101例（80%），疾病进展（PD）7例（5%），无完全缓解。栓塞剂类型之间存在差异：PR分别为7%和77%，SD分别为88%和8%，PD分别为5%和15%，DEB组和PEG组的疾病控制率分别为95%和85%。最常见的副作用为：腹痛、发热、恶心和转氨酶升高。